Publicacions en què col·labora amb Javier Cortés Castán (14)

2022

  1. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

  2. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  3. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  4. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

  5. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2020

  1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

    Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998

  2. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

    Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

  2. Phase 2 Study of Trabectedin in Patients With Hormone Receptor–Positive, HER-2–Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene

    Clinical Breast Cancer, Vol. 16, Núm. 5, pp. 364-371

2009

  1. Prognostic and predictive factors and genetic analysis of early breast cancer

    Clinical and Translational Oncology